Isgren, Anniella http://orcid.org/0000-0003-1901-6988
Göteson, Andreas http://orcid.org/0000-0001-6118-6054
Holmén-Larsson, Jessica
Pelanis, Aurimantas
Sellgren, Carl
Joas, Erik
Sparding, Timea
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Smedler, Erik
Jakobsson, Joel
Landén, Mikael http://orcid.org/0000-0002-4496-6451
Article History
Received: 1 February 2022
Revised: 21 July 2022
Accepted: 25 July 2022
First Online: 19 August 2022
Competing interests
: ML declares that he has received lecture honoraria from Lundbeck pharmaceutical. JJ declares that he was an employee at AstraZeneca pharmaceutical 2017–2019, and JHL declares that she is a current employee at AstraZeneca pharmaceutical. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. Other authors declare no competing interests.